Estimated reading time: 1 minute
Mounjaro deaths in the United Kingdom have climbed to 216 cases—a 300% surge from 2024 to 2025. Families grieve. Hospital protocols scramble. Coroners issue warnings.
Yet as this death toll mounts, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) appears poised to approve Foundayo, another GLP-1 weight-loss drug from Eli Lilly.
The message is stark: the same regulator that failed to prevent hundreds of deaths from one GLP-1 agonist is now fast-tracking approval for another. The approval rush does not pause for the bereaved. It accelerates past the bodies.
The Death Toll
On August 6, 2026, karmactive published an investigation detailing 216 Mounjaro deaths across the United Kingdom. The numbers demanded attention: a tripling of fatalities in twelve months.
Corporate Influence
Eli Lilly’s influence over UK pharmaceutical regulation is substantial but rarely scrutinized. The company maintains extensive relationships with MHRA advisory committees, funds medical education, and supports research institutions informing regulatory policy.